Imaging beta-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.

Article Details

Citation
Copy to clipboard

Heurling K, Leuzy A, Zimmer ER, Lubberink M, Nordberg A

Imaging beta-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.

Eur J Nucl Med Mol Imaging. 2016 Feb;43(2):362-73. doi: 10.1007/s00259-015-3208-1. Epub 2015 Oct 6.

PubMed ID
26440450 [ View in PubMed
]
Abstract

In Alzheimer's disease (AD), the deposition of beta-amyloid (Abeta) is hypothesized to result in a series of secondary neurodegenerative processes, leading ultimately to synaptic dysfunction and neuronal loss. Since the advent of the first Abeta-specific positron emission tomography (PET) ligand, (11)C-Pittsburgh compound B ([(11)C]PIB), several (18)F ligands have been developed that circumvent the limitations of [(11)C]PIB tied to its short half-life. To date, three such compounds have been approved for clinical use by the US and European regulatory bodies, including [(18)F]AV-45 ([(18)F]florbetapir; Amyvid), [(18)F]-BAY94-9172 ([(18)F]florbetaben; Neuraceq) and [(18)F]3'-F-PIB ([(18)F]flutemetamol; Vizamyl). The present review aims to summarize and discuss the currently available knowledge on [(18)F]flutemetamol PET. As the (18)F analogue of [(11)C]PIB, [(18)F]flutemetamol may be of use in the differentiation of AD from related neurodegenerative disorders and may help with subject selection and measurement of target engagement in the context of clinical trials testing anti-amyloid therapeutics. We will also discuss its potential use in non-AD amyloidopathies.

DrugBank Data that Cites this Article

Drugs